id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1978-N-0018-0750,FDA,FDA-1978-N-0018,Letter from King & Spalding on behalf of Givaudan-Roure Corporation to FDA CDER,Other,Letter(s),2012-11-13T05:00:00Z,2012,11,2012-11-13T05:00:00Z,,2019-07-22T12:13:55Z,,0,0,090000648055a1e5
FDA-1978-N-0018-0749,FDA,FDA-1978-N-0018,"FDA/CDER, Division of Nonprescription Regulation Development to Energizer Personal Care - Letter",Other,Letter(s),2012-07-09T04:00:00Z,2012,7,2012-07-09T04:00:00Z,,2012-07-09T15:58:58Z,,0,0,090000648108097a
FDA-1978-N-0018-0748,FDA,FDA-1978-N-0018,"FDA/CDER to Surrette Associates, LLC - Petition Denial",Other,Denial of Petition,2012-06-04T04:00:00Z,2012,6,2012-06-04T04:00:00Z,,2012-06-04T15:39:17Z,,0,0,090000648102ef35
FDA-1978-N-0018-0746,FDA,FDA-1978-N-0018,Labeling and Effectiveness Testing; Sunscreen Drug Products for Over-the-Counter Human Use; Delay of Compliance Dates,Rule,Final Rule,2012-05-11T04:00:00Z,2012,5,2012-05-11T04:00:00Z,2012-05-22T03:59:59Z,2012-05-20T02:00:15Z,2012-11390,0,0,090000648100adc0
FDA-1978-N-0018-0744,FDA,FDA-1978-N-0018,HumphreyLine - Letter,Other,Letter(s),2012-04-25T04:00:00Z,2012,4,2012-04-25T04:00:00Z,,2012-04-25T20:29:37Z,,0,0,0900006480ffb145
FDA-1978-N-0018-0745,FDA,FDA-1978-N-0018,HumphreyLine - Letter,Other,Letter(s),2012-04-25T04:00:00Z,2012,4,2012-04-25T04:00:00Z,,2012-04-25T20:30:24Z,,0,0,0900006480ffb253